Currently, four US Food and Drug Administration (FDA)‐approved small molecules (sorafenib, regorafenib, lenvatinib, and cabozantinib) for HCC treatment are multiple receptor tyrosine kinase inhibitors and showed limited therapeutic efficacy in the treatment of HCC patients. The gene discussed is NTRK1; the disease is hepatocellular carcinoma.